Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Pro Medicus (ASX:PME) Rallies on $23m Maryland Contract. Is This the Dip Investors Should Be Buying?

Pro Medicus jumps on new US contract Pro Medicus (ASX:PME) jumped more than 8% on Wednesday after sealing a five-year, A$23 million contract with the University of Maryland Medical System. The deal will roll out PME's cloud-based Visage 7 imaging platform across a network of 11 hospitals and more than 150 care locations. Good news,…

ByUjjwal MaheshwariApril 9, 2026

Mesoblast (ASX:MSB) Falls 7% Despite Record US$30.3M Ryoncil Quarter- Is This the Dip to Buy?

Mesoblast Shares Fall Despite Record Sales Mesoblast (ASX: MSB) shares fell around 7% on Tuesday, trading near A$1.98, after the company reported its best-ever quarterly Ryoncil sales. Net sales for the quarter ended March 31, 2026, came in at US$30.3 million, with strong February and March demand making up for a slow January. On the…

ByUjjwal MaheshwariApril 8, 2026

These 2 ASX Healthcare Stocks Are Quietly Cashing In on the AI Revolution

ASX Healthcare Stocks Benefiting From AI Artificial intelligence is reshaping healthcare faster than most investors realise. Hospital imaging systems, pathology labs, and diagnostic platforms are all being transformed by AI tools that improve speed, cut costs, and expand margins. Yet most of the market is still looking at chipmakers and data centres for AI exposure.…

ByUjjwal MaheshwariApril 7, 2026

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the back of gold price momentum or activity from neighbouring peers. With biotech it is all on the success of the individual company. The science is extraordinary…

ByNick SundichApril 7, 2026

The Long Goodbye: Why Australian Active Fund Managers Are Running Out of Road

Australian Active Fund Managers are struggling, make no mistake. Hitting home the point yesterday were reports that Ox Capital Management — a boutique emerging markets specialist led by veteran investor Joseph Lai; had entered formal wind-up proceedings on March 27 2026. This wind up was not the first, and likely won't be the last. So each…

ByNick SundichApril 2, 2026

Here are 5 ASX Stocks That Should Be Merged or Be Acquired, and Why the Logic Is Compelling

Despite the dour state of the markets right now, it could be time for certain ASX stocks that should be merged or be acquired to go ahead. With private equity sitting on nearly USD$440bn in uncommitted capital, a more permissive regulatory environment for smaller deal-making, and a wave of ASX small and mid-caps trading at…

ByNick SundichApril 1, 2026

Sigma Healthcare rerating rests on delivering $100m merger synergies

Sigma Healthcare (ASX: SIG) now turns on one fact above all others: the Chemist Warehouse merger has transformed a low-growth wholesaler into a scaled pharmacy retail and distribution group, and management has already lifted the expected synergy prize to $100m a year by FY29 from $60m. That upgrade, announced in October, was the clearest signal…

ByCharlie YouldenMarch 31, 2026

Here Are 6 Questions Investors Need To Ask About Their Portfolio To Get The Best Possible Returns!

There are hard questions investors need to ask about their portfolio every now and again, because anyone telling you there's such a thing as a 'set and forget' investment is wrong. Markets evolve, company fundamentals shift, and macro conditions change, yet many portfolios are left largely unchecked. The most rational approach is to periodically interrogate…

ByNick SundichMarch 31, 2026

The 4 Best ASX Healthcare Stocks to Buy as the Sector Trades at Two-Decade Valuation Lows

4 ASX Healthcare Stocks to Buy at Valuation Lows ASX healthcare stocks have had a brutal run. Five years of underperformance, persistent earnings downgrades, and aggressive rate hikes have pushed the sector to levels many investors have not seen in a generation. According to Wilsons Advisory, ASX 100 healthcare stocks now trade at two-decade lows…

ByUjjwal MaheshwariMarch 30, 2026

Lumos Diagnostics (ASX: LDX) Falls Despite FDA Win- Here’s Why the Dip Could Be a Buying Opportunity

Lumos Diagnostics Falls After FDA Waiver Lumos Diagnostics (ASX: LDX) slipped around 3.8% on Friday despite announcing one of the most important milestones in its history. The US Food and Drug Administration granted a CLIA waiver for its flagship FebriDx test, a development that expands the company's addressable US market by 15 times. The dip…

ByUjjwal MaheshwariMarch 30, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Pro Medicus (ASX:PME) Rallies on $23m Maryland Contract. Is This the Dip Investors Should Be Buying?

Mesoblast (ASX:MSB) Falls 7% Despite Record US$30.3M Ryoncil Quarter- Is This the Dip to Buy?

These 2 ASX Healthcare Stocks Are Quietly Cashing In on the AI Revolution

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

The Long Goodbye: Why Australian Active Fund Managers Are Running Out of Road

Here are 5 ASX Stocks That Should Be Merged or Be Acquired, and Why the Logic Is Compelling

Sigma Healthcare rerating rests on delivering $100m merger synergies

Here Are 6 Questions Investors Need To Ask About Their Portfolio To Get The Best Possible Returns!

The 4 Best ASX Healthcare Stocks to Buy as the Sector Trades at Two-Decade Valuation Lows

Lumos Diagnostics (ASX: LDX) Falls Despite FDA Win- Here’s Why the Dip Could Be a Buying Opportunity

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here